Cologne, Germany — We’ve hit our first big milestone here at Endpoints News. Today marks our 100th issue, brought to you from Germany, where I’ve been spending a few days at Bio-Europe with a few thousand of my closest friends and readers.
Over the past few months, my partner, Arsalan Arif, and I have been refining a unique approach to biotech news, focusing on the ups and downs that influence the global industry with the unique perspective you get from 14 years in the front lines of this business. Biotech has changed a lot in just the last few years, and it’s been a lot of fun forging our coverage of the field.
At this point, it’s fairly rare for anything to be completely new. Most of the news in biotech is part of a continuing story about drug development programs, pipeline advances and setbacks, new discoveries in established fields and the growing debate over drug pricing that will likely dominate much of the conversation in 2017.
During these past 100 issues, Arsalan has made a lot of progress on the website (still under construction, but making progress) while I’ve been getting the word out about the transition from…wherever that was. We both work on the main edition, while Arsalan edits the morning report and manages Marco, our Twitter news bot. We’ve gathered more than 12,000 email subscribers over 4 months, concentrated heavily in the US and Europe. That’s on top of hundreds of thousands of unique web visitors.
We also pulled off the first quarterly industry survey with more than 100 top biotech execs — set to grow to 150 by the end of this year. And we’ve set up our first Endpoints News event, with an upcoming Executive Breakfast Session at JP Morgan in January where we’ll be tackling the drug pricing debate. Stay tuned for more details.
These days, we now have a database that includes enough stories worth searching. And I’m looking forward to adding a few million words in time.
As always, we’re looking for as much feedback as we can get on our coverage. All ideas are welcome. And in the meantime, if you’d like to support our work, as so many of you have expressed, there’s no better way than suggesting to a friend or colleague to subscribe today. Word-of-mouth remains our single best promo. Here’s the link.
On to issue #200. — Cheers, John Carroll, Editor
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription